PURE Bioscience, Inc. (PURE) Fair Value 2026

PURE · Household & Personal Products ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.4 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-27, PURE Bioscience, Inc. (PURE) trades at $0.09, versus a $0.02 median fair value across its 2 active models — 73.6% below the current price. QOC: 5.4/10. Value Trap Risk: 34/100 (LOW). 2/13 models active.

Key Facts

Ticker
PURE
Price
$0.09
Quality Score
5.4/10
Value Trap Risk
34/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is PURE Bioscience, Inc. (PURE) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, PURE Bioscience, Inc. (PURE) appears overvalued as of : the median of 2 independent fair value estimates is $0.02, 73.6% below the current price of $0.09. Estimates range from $0.00 to $0.04. PURE scores 5.4/10 on fundamental quality and 34/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. PURE’s -73.6% gap is wider than that market norm, and the Household & Personal Products sector median is -6.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy PURE Bioscience, Inc. Stock in 2026? →

What Fair Value Does Each Model Give PURE?

2 Intrinsic Value Models vs. Current Price ($0.09)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.04 -50.1%
Option-Based · Medium Conviction
 $0.00 -97.0%

All Models Active

All 2 models are displayed above.

What Is PURE Bioscience, Inc. (PURE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, PURE Bioscience, Inc.'s intrinsic value is estimated at $0.02. Trading at its current price of $0.09, the valuation engine raises significant caution: 2 of 2 models flag downside risk, projecting a median implied return of -73.6%. Notably, Dynamic NAV sees the most upside at -50.1% (fair value: $0.04), while PWERM is the most conservative at -97.0% ($0.00). The spread between these extremes — +46.9% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About PURE?

2 of 13 models are currently active for PURE. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for PURE is $0.02 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does PURE Rank in Household & Personal Products?

Among 35 Household & Personal Products stocks, PURE ranks #28 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.

PURE Bioscience, Inc.'s positioning within the Household & Personal Products segment means that e-commerce penetration rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including private label penetration — shape both the opportunity set and risk profile.

Is PURE a Value Trap?

CirclFi's Value Trap algorithm assigns PURE a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for PURE Bioscience, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, PURE Bioscience, Inc. earns a quality score of 5.4/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +46.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PURE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PURE's 2 active models, average confidence is 41%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy PURE Bioscience, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Household & Personal Products Stocks Should You Also Analyze?

10 related Household & Personal Products stocks with 13-model coverage

WALDWaldencast plcQOC 5.7XAGELongevity Health Holdings, Inc.QOC 4.7SKINSkinHealth Systems Inc.QOC 6.0GROVGrove Collaborative Holdings, Inc.QOC 4.7COTYCoty Inc.QOC 6.1SKVISkinvisible, Inc.QOC 4.4IPARInterparfums, Inc.QOC 9.3NUSNu Skin Enterprises, Inc.QOC 7.7ELThe Estée Lauder Companies Inc.QOC 6.8PGThe Procter & Gamble CompanyQOC 8.8

Read investment analysis: WALD · XAGE · SKIN · GROV · COTY · SKVI · IPAR · NUS · EL · PG

Which Other Stocks Have a Similar Quality Score to PURE?

7 companies across all industries closest to PURE’s Quality of Company score of 5.4/10.

NEOVNeoVolta Inc.QOC 5.4ENHAEnhanced Group Inc.QOC 5.4IMUXImmunic, Inc.QOC 5.4WDWalker & Dunlop, Inc.QOC 5.4TWOTwo Harbors Investment Corp.QOC 5.4APAmpco-Pittsburgh CorporationQOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NEOV · ENHA · IMUX · WD · TWO · AP · NVDA

What Else Do Investors Ask About PURE Bioscience, Inc.’s Valuation?

What is PURE Bioscience, Inc.'s intrinsic value in 2026?

CirclFi puts PURE Bioscience, Inc. (PURE)'s intrinsic value at $0.02 — the median of 2 independent model estimates as of 2026-08-27, ranging from $0.00 to $0.04. The Quality of Company score is 5.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PURE overvalued or undervalued right now?

At $0.09, 0 of 2 active models suggest PURE may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $0.02, 73.6% below the current price of $0.09 — a consensus view that PURE is overvalued. The assessment depends on which methodology best fits PURE Bioscience, Inc.'s business model in Household & Personal Products.

What does a Quality of Company score of 5.4 mean for PURE?

PURE Bioscience, Inc.'s QOC of 5.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PURE?

CirclFi analyzes PURE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is PURE a value trap in 2026?

PURE Bioscience, Inc.'s Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, PURE Bioscience, Inc. (PURE) has a median fair value of $0.02 — 73.6% below the current price of $0.09 — as of 2026-08-27.” Source: circlfi.com/stock/PURE/ · Methodology
Primary sources for this PURE valuation
  • Financial statements: PURE Bioscience, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001006028) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PURE as of ; valuations recomputed .